AstraZeneca Q2 Adj. EPS $0.99 Misses $1.20 Estimate, Sales $12.98B Beat $12.75B Estimate
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca (NASDAQ:AZN) reported Q2 adjusted EPS of $0.99, missing the $1.20 estimate, but sales of $12.98B beat the $12.75B estimate. EPS decreased by 7.91% YoY, while sales increased by 13.73% YoY.
July 25, 2024 | 6:28 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
AstraZeneca's Q2 adjusted EPS of $0.99 missed the $1.20 estimate, a 17.5% shortfall, and a 7.91% decrease YoY. However, sales of $12.98B beat the $12.75B estimate, a 1.83% increase, and a 13.73% YoY growth.
The mixed results, with EPS missing estimates but sales beating expectations, create a neutral short-term outlook. The EPS miss may concern investors, but strong sales growth could offset some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100